What Chloral Hydrate-Odan Treats: Main Uses and Benefits

Chloral Hydrate is classified as a sedative-hypnotic agent, generally used in situations involving certain distressing symptoms and relevant when short-term symptomatic assistance is needed.

The medication is commonly used to help with symptoms related to acute, severe difficulty falling asleep, to manage pronounced anxiety and agitation before medical or diagnostic procedures, and for easing episodes of central nervous system hyper-excitement, such as those seen in certain withdrawal scenarios.

“It is primarily applied in acute therapeutic contexts to help manage symptoms that have become intense or disruptive.”

This approach supports patients during episodes of heightened discomfort and tension. It offers symptomatic relief that helps patients cope more steadily with difficult episodes, contributing to easing the overall symptom load during these phases.

---

Quick Fact: Relief for Severe Sleeplessness

This medication is commonly used to address acute symptoms that interfere with daily functioning, specifically profound, short-term insomnia, where it contributes to easing the symptom load associated with difficulty initiating sleep.

Regulatory References

1. Health Canada Product Monograph

Official Eligibility and Non-Eligibility Rules

Regulatory documents define strict population eligibility criteria for Chloral Hydrate-Odan, primarily based on the patient's existing health status and age.

---

Absolute Contraindications

Use of this medicine is absolutely contraindicated in patients with marked hepatic impairment or marked renal impairment, due to the drug’s metabolism and clearance requirements. Individuals with a known hypersensitivity to chloral hydrate are also prohibited from use. A conditional prohibition exists for patients with severe cardiac disease, for whom high doses are officially contraindicated.

---

Restricted and Cautionary Use

Use is established but restricted for pediatric patients and older adults (geriatrics); both groups require special caution due to heightened physiological sensitivity. For pregnant women, use is restricted and advised only when clearly necessary, as the drug crosses the placental barrier. Lactating women are also advised to use the medication with caution. Furthermore, oral administration should be avoided in patients with pre-existing conditions like gastritis or duodenal ulcers. Caution is also required for patients with a history of substance use disorder.

Interactions with other medicines and products

Chloral Hydrate has documented interaction patterns that primarily involve pharmacodynamic reinforcement and exposure alteration, as defined in regulatory labeling. Officially documented interactions require strict adherence to restrictions on co-administration with numerous drug classes and substances.

Formal Contraindications and Prohibitions

The co-administration of Chloral Hydrate followed by intravenous Furosemide is a contraindicated combination, posing a risk of a hypermetabolic state and variable blood pressure. Use is also formally restricted in patients with severe hepatic or renal impairment due to the risk of the drug and its metabolite accumulation.

Interactions Due to Enhanced Effects

The central sedative effect is enhanced when Chloral Hydrate is combined with alcohol (ethanol) or any other Central Nervous System (CNS) depressants, including but not limited to antipsychotics, narcotic analgesics, and sedative antihistamines. Concomitant use with these substances must be avoided. Furthermore, co-administration with medicines that prolong the QT interval on an electrocardiogram can lead to cardiac arrhythmias.

Exposure Monitoring Requirements

When Chloral Hydrate is introduced into the regimen of a patient taking oral anticoagulants (such as Warfarin), careful and frequent monitoring of the prothrombin time (INR) is required due to the possibility of an altered anticoagulant effect. Regulatory documents note that no formal pharmacokinetic assessments with other therapeutic medicinal products have been conducted. In elderly patients, co-administration with psychotropics or anticholinergics may increase the risk of delirium.

The action of Chloral Hydrate-Odan is driven entirely by its active metabolite, Trichloroethanol, which selectively modulates inhibitory signaling pathways in the central nervous system (CNS).

Augmenting gamma-Aminobutyric Acid Inhibition

The primary mechanism involves the active metabolite functioning as a Positive Allosteric Modulator (PAM) of the gamma-Aminobutyric acid type A receptor ( GABA A receptor), a major inhibitory channel in the brain. Trichloroethanol binds to a site distinct from the GABA neurotransmitter binding site, which consequently enhances the receptor's sensitivity to GABA. This interaction results in an enhanced inhibitory signal across affected neurons.

Initiating the CNS Depressive Cascade

The enhanced GABA A activity causes a massive influx of negatively charged chloride ions ( Cl^-) into the neuron, a process known as hyperpolarization. This cellular change drastically lowers the firing rate of nerve cells throughout the CNS. The widespread physiological slowing of electrical activity initiates a state of generalized CNS depression.

Mechanistic Constraints

The mechanism is subject to functional constraints. Continuous engagement of the GABA A receptor system can lead to tolerance, a biological adaptation where the receptor complex becomes less responsive to Trichloroethanol, indicating that the mechanism's influence on the pathway diminishes with chronic exposure.

Chloral Hydrate-Odan is an oral liquid that is used according to strict, label-based dosage and timing schedules for short-term administration only. The route of administration is oral, with other formulations allowing for rectal use where necessary.

Official Dosing and Administration

Administration of the oral solution should occur 15 to 30 minutes before bedtime when used for sleep induction. For routine sedative use, the medication is often directed to be taken in divided doses, typically three times daily, administered after meals.

The usual adult hypnotic dose ranges from 500 mg to 1 g (0.5–1 g) as a single dose. The maximum total daily intake for adults and children 12 years and over must not exceed 2 g (2000 mg).

Preparation and Duration Rules

To manage potential gastrointestinal irritation, the oral solution must be diluted with water, milk, or fruit juice immediately prior to administration. The liquid should never be taken undiluted. If a dose is missed, patients are instructed to omit the missed dose and take the next dose at the scheduled time; a double dose must not be taken.

Treatment is intended for short-term use only and should not exceed two consecutive weeks. Following prolonged use, the dose must be slowly tapered before discontinuation, as directed by a healthcare provider, rather than stopped abruptly. Specific dose reductions are often required for older or frail adults and for patients with mild-to-moderate liver impairment; use is contraindicated in cases of severe renal or hepatic impairment.

Research Evidence / Overview of Studies for Chloral Hydrate-Odan

---

Evidence for Use in Short-term Sleep Management

Research examining Chloral Hydrate-Odan was studied for severe, short-term insomnia, based on historical clinical trials and more recent open-label Real-World Evidence (RWE) studies applied in research examining patient-reported experiences. These studies explore its application in research contexts involving fluctuating or unstable symptoms, where difficulty falling asleep was a measured outcome. Researchers designed these studies to monitor how symptoms evolved in the observed populations, with outcomes related to functional imbalance and activity level.

Studies explored the drug's effect on subjective measures like the validated Insomnia Severity Index (ISI) score. The findings describe patterns observed during the study periods, such as changes measured in the ISI scores. The evidence level for this indication is described as Moderate; the core data for adult populations is older, and recent evidence is primarily derived from open-label RWE studies.

---

Evidence for Use in Procedural Sedation

The research base for using this medicine to achieve stillness during diagnostic and minor procedures includes a substantial number of studies, particularly in pediatrics. These studies include many systematic reviews, meta-analyses, and Randomized Controlled Trials (RCTs) that compare the medicine to other sedative agents. Research has examined the medicine for conditions involving periods of heightened symptoms where immobilization is necessary.

Studies monitored outcomes related to functional imbalance, primarily evaluating the Sedation Success Rate—defined by the ability to complete the required procedure without disruption. The evidence level for this research area is also generally categorized as Moderate. The evidence quality varies across studies, and comparative evidence against some newer agents is described as lacking.

---

What is Still Uncertain About Chloral Hydrate-Odan

There is limited information for long-term outcomes regarding the use of Chloral Hydrate-Odan, as follow-up durations in the treatment of insomnia were limited. Research exploring chronic or extended use is not well characterized in the official clinical record. Comparative evidence that directly contrasts Chloral Hydrate-Odan with newer sedative and hypnotic medicines often has findings where certainty remains low.

Key Studies & References

1. PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION (CHLORAL HYDRATE SYRUP ODAN)
2. Chloral hydrate - LiverTox - NCBI Bookshelf

Common questions about Chloral Hydrate-Odan (FAQ)

Q: What is the typical dose for an adult to help with sleep?

According to the official product information, the dose for adults to help with sleep typically falls within a specific range, based on regulatory labeling. Regulatory labeling states that the maximum total daily intake for adults is 2 grams. The specific dose and timing schedule should be determined by a healthcare professional.

---

Q: Are there any conditions or diseases that would make it unsafe for me to take this medicine?

Official regulatory documents list several conditions where use of this medicine is prohibited, known as contraindications. These include marked impairment of the liver or kidneys, severe heart disease (especially when high doses are considered), and existing active gastritis or duodenal ulcers. The determination of whether this medication is appropriate requires a review of your full medical history by a qualified healthcare professional.

---

Q: What is the most serious side effect I should watch out for?

Official regulatory documents list several serious adverse reactions that are clinically significant for patients to be aware of. These include severe cardiac events, such as certain abnormal heart rhythms, as well as significant breathing problems like respiratory depression or life-threatening airway obstruction. This information details potential risks that have been documented in safety summaries.

---

Q: Can I stop taking Chloral Hydrate-Odan abruptly?

Official guidance indicates that abrupt discontinuation of this medication after prolonged use is not advised. Treatment is intended to be short-term and generally should not exceed two consecutive weeks. If the medicine has been taken for an extended period, the dose must be slowly reduced, or tapered, before stopping completely due to the potential for a withdrawal syndrome.

---

Q: What should I do if I take too much Chloral Hydrate-Odan (Overdose symptoms)?

Official regulatory labels include a section on overdose, indicating that taking too much can cause very severe side effects. These may include profound central nervous system depression, significant difficulty breathing, and severe low blood pressure. A suspected overdose is considered a medical emergency and requires immediate professional attention.

---

Q: What are the ingredients in the oral solution besides Chloral Hydrate?

Chloral Hydrate-Odan is a single-active-ingredient product, meaning Chloral Hydrate is the only medicine in the solution. The oral liquid is a syrup or solution that uses a water-based liquid, known as an aqueous vehicle. A complete list of inactive ingredients (excipients) for the specific formulation is available within the official regulatory labeling.

Official Storage and Disposal Requirements

Chloral Hydrate-Odan syrup must be stored under controlled conditions to maintain stability and ensure safety, as required by regulatory labeling. The medication must be kept in a light-resistant, tight container and stored away from excessive heat and moisture.

Storage Constraints

Condition	Regulatory Requirement
Temperature	Store below 40°C; 15 C to 30 C is preferred.
Freezing	Do not freeze the syrup.
Security	Store securely due to its status as a controlled substance.
Protection	Keep out of the sight and reach of children.

Unused or expired Chloral Hydrate-Odan must be safely discarded. Official disposal guidelines typically mandate returning the product to a pharmacy for proper take-back. If a take-back program is unavailable, the product should be mixed with an undesirable substance and placed in a sealed container before disposal in the household trash.